0750 GMT - Novartis's 2025 guidance is constructive and beats consensus expectations, Intron Health analysts say in a note. The Swiss pharma giant's guidance is for mid-to-high single-digit sales growth, which is a 3% lift to consensus sales and EBIT, the analysts say. "Whilst we were worried about the impact of foreign-currency effects, Part D reform [U.S. Medicare drug pricing reform] and [multiple-sclerosis drug] Kesimpta pricing, this guidance looks very strong and appears higher than consensus," they say.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 31, 2025 02:50 ET (07:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。